Thus, we speculated that nasally administered postimmunobiotics contribute to the generation of trained alveolar macrophages during RSV infection or TLR3 activation, in this way increasing the protection against secondary pneumococcal pneumonia [10,11,12,13,14]. Here, TLR3 is linked to pneumococcal pneumonia.